NEW YORK – Tango Therapeutics on Monday began treating patients with STK11-mutant cancers in a Phase I/II trial of its CoREST inhibitor TNG260 plus Merck's Keytruda (pembrolizumab).
The first-in-human trial will include 126 patients with advanced or metastatic STK11-mutant solid tumors. Researchers will enroll patients with non-small cell lung, endometrial, pancreatic, cervical, breast, and unknown primary cancers in the trial, along with other solid tumors. The trial features planned dose-expansion cohorts of patients with STK11-mutant, KRAS-mutant, and STK11-mutant, KRAS wild-type NSCLC.
TNG260 is designed to address checkpoint inhibitor resistance through STK11 loss of function by targeting the CoREST, or co-repressor of repressor element-1 silencing transcription, complex. The CoREST complex regulates immunomodulatory protein expression in STK11-mutant cancers, according to the company.
In April, the US Food and Drug Administration granted Tango fast-track designation to study TNG260 in combination with an anti-PD-1 antibody in patients with STK11-mutant NSCLC.
Earlier this month, Boston-based Tango also began a Phase I/II trial of its PRMT5 inhibitor, TNG462, in patients with MTAP-deleted solid tumors.